Chris Howerton
Stock Analyst at Jefferies
(2.62)
# 2,031
Out of 5,154 analysts
68
Total ratings
43.4%
Success rate
19.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Howerton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VNDA Vanda Pharmaceuticals | Maintains: Hold | $5 → $7.5 | $7.89 | -4.94% | 12 | Dec 31, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $79 → $125 | $57.73 | +116.53% | 3 | Dec 11, 2025 | |
| ARDX Ardelyx | Maintains: Buy | $11 → $8 | $6.19 | +29.24% | 5 | Jan 2, 2025 | |
| MIST Milestone Pharmaceuticals | Downgrades: Hold | $8 → $4 | $1.58 | +153.16% | 4 | Jun 20, 2023 | |
| VERU Veru Inc. | Upgrades: Hold | $10 | $2.47 | +304.86% | 3 | Jun 7, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Hold | $320 → $352 | $1.48 | +23,683.78% | 2 | Mar 10, 2023 | |
| AVTX Avalo Therapeutics | Downgrades: Underperform | $720 | $17.31 | +4,059.45% | 2 | Feb 8, 2023 | |
| CGEN Compugen | Downgrades: Underperform | $0.5 | $2.08 | -75.96% | 2 | Feb 8, 2023 | |
| URGN UroGen Pharma | Downgrades: Hold | $35 → $10 | $20.46 | -51.12% | 1 | Feb 8, 2023 | |
| APLS Apellis Pharmaceuticals | Downgrades: Hold | $70 → $40 | $20.07 | +99.30% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $57 → $61 | $28.33 | +115.32% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $90 | $162.33 | -44.56% | 3 | Sep 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $0.30 | +6,555.57% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $66 | $29.43 | +124.26% | 9 | Sep 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $4.94 | +345.34% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $1.12 | +1,775.00% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $0.63 | +3,381.56% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $21 | $22.16 | -5.23% | 6 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $80 → $580 | $9.13 | +6,252.68% | 2 | Aug 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $63 → $60 | $2.25 | +2,566.67% | 1 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 | $33.87 | -52.76% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $92.09 | -70.68% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,200 | $1.28 | +93,774.68% | 1 | May 26, 2020 |
Vanda Pharmaceuticals
Dec 31, 2025
Maintains: Hold
Price Target: $5 → $7.5
Current: $7.89
Upside: -4.94%
Structure Therapeutics
Dec 11, 2025
Maintains: Buy
Price Target: $79 → $125
Current: $57.73
Upside: +116.53%
Ardelyx
Jan 2, 2025
Maintains: Buy
Price Target: $11 → $8
Current: $6.19
Upside: +29.24%
Milestone Pharmaceuticals
Jun 20, 2023
Downgrades: Hold
Price Target: $8 → $4
Current: $1.58
Upside: +153.16%
Veru Inc.
Jun 7, 2023
Upgrades: Hold
Price Target: $10
Current: $2.47
Upside: +304.86%
BioXcel Therapeutics
Mar 10, 2023
Downgrades: Hold
Price Target: $320 → $352
Current: $1.48
Upside: +23,683.78%
Avalo Therapeutics
Feb 8, 2023
Downgrades: Underperform
Price Target: $720
Current: $17.31
Upside: +4,059.45%
Compugen
Feb 8, 2023
Downgrades: Underperform
Price Target: $0.5
Current: $2.08
Upside: -75.96%
UroGen Pharma
Feb 8, 2023
Downgrades: Hold
Price Target: $35 → $10
Current: $20.46
Upside: -51.12%
Apellis Pharmaceuticals
Nov 10, 2022
Downgrades: Hold
Price Target: $70 → $40
Current: $20.07
Upside: +99.30%
Oct 14, 2022
Upgrades: Buy
Price Target: $57 → $61
Current: $28.33
Upside: +115.32%
Sep 30, 2022
Maintains: Buy
Price Target: $92 → $90
Current: $162.33
Upside: -44.56%
Nov 30, 2021
Initiates: Buy
Price Target: $20
Current: $0.30
Upside: +6,555.57%
Sep 17, 2021
Initiates: Buy
Price Target: $66
Current: $29.43
Upside: +124.26%
Aug 23, 2021
Initiates: Buy
Price Target: $22
Current: $4.94
Upside: +345.34%
Aug 10, 2021
Initiates: Buy
Price Target: $21
Current: $1.12
Upside: +1,775.00%
May 25, 2021
Initiates: Buy
Price Target: $22
Current: $0.63
Upside: +3,381.56%
Apr 6, 2021
Downgrades: Hold
Price Target: $40 → $21
Current: $22.16
Upside: -5.23%
Aug 11, 2020
Upgrades: Buy
Price Target: $80 → $580
Current: $9.13
Upside: +6,252.68%
Aug 7, 2020
Downgrades: Underperform
Price Target: $63 → $60
Current: $2.25
Upside: +2,566.67%
Aug 5, 2020
Downgrades: Hold
Price Target: $16
Current: $33.87
Upside: -52.76%
Jul 15, 2020
Initiates: Buy
Price Target: $27
Current: $92.09
Upside: -70.68%
May 26, 2020
Initiates: Buy
Price Target: $1,200
Current: $1.28
Upside: +93,774.68%